Navidea Biopharmaceuticals (NAVB) Competitors $0.01 +0.01 (+1,566.67%) As of 05/12/2025 02:19 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOptions ChainSEC FilingsTrendsBuy This Stock NAVB vs. CANF, OGEN, SPRC, MBIO, GLTO, SBFM, IMCC, KZIA, SXTP, and CNSPShould you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include Can-Fite BioPharma (CANF), Oragenics (OGEN), SciSparc (SPRC), Mustang Bio (MBIO), Galecto (GLTO), Sunshine Biopharma (SBFM), IM Cannabis (IMCC), Kazia Therapeutics (KZIA), 60 Degrees Pharmaceuticals (SXTP), and CNS Pharmaceuticals (CNSP). These companies are all part of the "pharmaceutical products" industry. Navidea Biopharmaceuticals vs. Can-Fite BioPharma Oragenics SciSparc Mustang Bio Galecto Sunshine Biopharma IM Cannabis Kazia Therapeutics 60 Degrees Pharmaceuticals CNS Pharmaceuticals Can-Fite BioPharma (NYSE:CANF) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability, valuation and community ranking. Which has more risk & volatility, CANF or NAVB? Can-Fite BioPharma has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Does the MarketBeat Community prefer CANF or NAVB? Can-Fite BioPharma received 10 more outperform votes than Navidea Biopharmaceuticals when rated by MarketBeat users. Likewise, 12.20% of users gave Can-Fite BioPharma an outperform vote while only 0.00% of users gave Navidea Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformCan-Fite BioPharmaOutperform Votes1012.20%Underperform Votes7287.80% Navidea BiopharmaceuticalsOutperform VotesNo VotesUnderperform Votes86100.00% Is CANF or NAVB more profitable? Company Net Margins Return on Equity Return on Assets Can-Fite BioPharmaN/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A Does the media refer more to CANF or NAVB? In the previous week, Navidea Biopharmaceuticals had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 1 mentions for Navidea Biopharmaceuticals and 0 mentions for Can-Fite BioPharma. Can-Fite BioPharma's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score. Company Overall Sentiment Can-Fite BioPharma Neutral Navidea Biopharmaceuticals Neutral Do analysts prefer CANF or NAVB? Can-Fite BioPharma currently has a consensus price target of $14.00, suggesting a potential upside of 1,189.61%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than Navidea Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Navidea Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders have more ownership in CANF or NAVB? 21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has preferable earnings and valuation, CANF or NAVB? Can-Fite BioPharma has higher revenue and earnings than Navidea Biopharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCan-Fite BioPharma$674K5.70-$7.63M-$1.79-0.61Navidea Biopharmaceuticals$8.13K123.17-$15.18MN/AN/A SummaryCan-Fite BioPharma beats Navidea Biopharmaceuticals on 9 of the 13 factors compared between the two stocks. Get Navidea Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAVB vs. The Competition Export to ExcelMetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$1.00M$2.65B$5.36B$19.56BDividend YieldN/A0.71%5.44%3.95%P/E RatioN/A7.6325.7234.92Price / Sales123.17384.28405.3435.26Price / CashN/A15.7538.3117.51Price / BookN/A5.796.744.75Net Income-$15.18M-$65.73M$3.23B$1.02B7 Day PerformanceN/A51.39%2.72%5.16%1 Month PerformanceN/A56.26%10.59%11.86%1 Year PerformanceN/A11.38%15.49%6.83% Navidea Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAVBNavidea BiopharmaceuticalsN/A$0.01+1,566.7%N/A-72.2%$1.00M$8,126.000.0010Analyst ForecastCANFCan-Fite BioPharma1.4625 of 5 stars$1.10-0.9%$14.00+1,172.7%-47.4%$3.89M$674,000.00-0.618Gap UpOGENOragenicsN/A$0.18+6.8%N/A-90.2%$3.87M$40,000.00-0.035News CoverageSPRCSciSparc1.3312 of 5 stars$0.35+2.3%N/A-71.8%$3.81M$1.31M0.004News CoverageMBIOMustang Bio0.5296 of 5 stars$1.13-3.0%$100.00+8,749.6%-91.3%$3.74MN/A-0.01100Positive NewsGap DownGLTOGalecto2.4642 of 5 stars$2.78+1.3%$10.00+260.4%-83.7%$3.67MN/A-0.1440Earnings ReportGap DownSBFMSunshine Biopharma2.9419 of 5 stars$1.35+8.0%$15.00+1,011.1%+51.3%$3.65M$34.87M-0.013Upcoming EarningsGap UpIMCCIM Cannabis0.3698 of 5 stars$1.61-2.4%N/A-62.5%$3.60M$54.03M-0.47340Upcoming EarningsGap DownKZIAKazia Therapeutics3.2909 of 5 stars$3.56-1.7%$57.50+1,515.2%-75.1%$3.59M$2.31M0.0012Positive NewsSXTP60 Degrees Pharmaceuticals0.3501 of 5 stars$2.42+1.3%N/A+115.1%$3.57M$607,574.00-0.243Analyst ForecastNews CoverageGap UpCNSPCNS Pharmaceuticals1.3145 of 5 stars$1.21+6.1%$25.00+1,966.1%-99.8%$3.56MN/A-0.025News CoverageGap UpTrading Halted Related Companies and Tools Related Companies Can-Fite BioPharma Competitors Oragenics Competitors SciSparc Competitors Mustang Bio Competitors Galecto Competitors Sunshine Biopharma Competitors IM Cannabis Competitors Kazia Therapeutics Competitors 60 Degrees Pharmaceuticals Competitors CNS Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NAVB) was last updated on 5/13/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NAVB Stock Free NAVB Stock Alerts